Literature DB >> 20498439

Biallelic TSC gene inactivation in tuberous sclerosis complex.

Peter B Crino1, Eleonora Aronica, Gordon Baltuch, Katherine L Nathanson.   

Abstract

BACKGROUND: A pivotal developmental question is whether tubers in tuberous sclerosis complex (TSC) form by germline and somatic TSC1 or TSC2 gene mutations. Loss of TSC1 or TSC2 in vitro and in vivo leads to mTORC1 cascade activation and ribosomal protein S6 phosphorylation (P-S6). Giant cells (GCs) in tubers exhibit S6 phosphorylation, suggesting cell-specific loss of TSC gene function.
METHODS: TSC1 and TSC2 gene mutations were investigated in DNA extracted from tuber sections (n = 6) and microdissected P-S6-labeled GCs by sequencing and loss of heterozygosity (LOH) analysis to define germline and somatic mutations.
RESULTS: A germline TSC1 mutation was defined in 1 case and TSC2 mutations were defined in 5 cases. LOH was not detected in whole tuber sections or microdissected P-S6-labeled GCs. TSC1 and TSC2 were sequenced in microdissected P-S6-immunolabeled GCs. In 5 specimens, a somatic mutation was identified in single GCs that was not detected in whole tuber sections or leukocyte DNA. Four somatic mutations were novel variants (1 nonsense and 3 missense mutations) and 1 additional nonsense somatic mutation was previously reported as a germline mutation. In 1 case, no somatic mutation was identified. There was reduced expression of TSC1 or TSC2 transcripts in the TSC1 or TSC2 associated specimens. In the cases containing a nonsense mutation, no transcript mRNA was detected, suggesting nonsense-mediated degradation.
CONCLUSIONS: We provide evidence to support the hypothesis that tubers form by biallelic TSC1 or TSC2 gene inactivation reflecting a "2-hit" mechanism of germline and somatic mutational events. AML = angiomyolipoma; DN = dysplastic neuron; FFPE = formalin fixed, paraffin embedded; GC = giant cell; H-E = hematoxylin and eosin; LOH = loss of heterozygosity; TSC = tuberous sclerosis complex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498439      PMCID: PMC2882213          DOI: 10.1212/WNL.0b013e3181e04325

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Nonsense-mediated RNA decay in the TSC1 gene suggests a useful tool pre- and post-positional cloning.

Authors:  Dharini Jeganathan; Margaret F Fox; Janet M Young; John R W Yates; John P Osborne; Sue Povey
Journal:  Hum Genet       Date:  2002-09-19       Impact factor: 4.132

2.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Authors:  Heidi L Kenerson; Lauri D Aicher; Lawrence D True; Raymond S Yeung
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

3.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

4.  Developmental lineage of cell types in cortical dysplasia with balloon cells.

Authors:  Phillip Lamparello; Marianna Baybis; John Pollard; Elly M Hol; David D Eisenstat; Eleonora Aronica; Peter B Crino
Journal:  Brain       Date:  2007-09       Impact factor: 13.501

5.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

6.  Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.

Authors:  Xinsheng Gao; Yong Zhang; Peter Arrazola; Okio Hino; Toshiyuki Kobayashi; Raymond S Yeung; Binggeng Ru; Duojia Pan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

7.  mTOR cascade activation distinguishes tubers from focal cortical dysplasia.

Authors:  Marianna Baybis; Jia Yu; Allana Lee; Jeff A Golden; Howard Weiner; Guy McKhann; Eleonora Aronica; Peter B Crino
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

8.  Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis.

Authors:  Hajime Miyata; Alexander C Y Chiang; Harry V Vinters
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

9.  Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.

Authors:  Erik J Uhlmann; Wen Li; Danielle K Scheidenhelm; Chia-Ling Gau; Fuyuhiko Tamanoi; David H Gutmann
Journal:  Glia       Date:  2004-08-01       Impact factor: 7.452

10.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Authors:  Andrew R Tee; Diane C Fingar; Brendan D Manning; David J Kwiatkowski; Lewis C Cantley; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

View more
  67 in total

1.  A Tuber-ful Animal Model of Tuberous Sclerosis At Last?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2012-01       Impact factor: 7.500

2.  Tuber-Less Models of Tuberous Sclerosis Still Provide Insights Into Epilepsy.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2015 May-Jun       Impact factor: 7.500

Review 3.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

4.  Postnatal neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration following single-cell Tsc1 deletion.

Authors:  David M Feliciano; Jennifer L Quon; Tiffany Su; M Morgan Taylor; Angélique Bordey
Journal:  Hum Mol Genet       Date:  2011-11-07       Impact factor: 6.150

5.  The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.

Authors:  Sharon W Way; Natalia S Rozas; Henry C Wu; James McKenna; R Michelle Reith; S Shahrukh Hashmi; Pramod K Dash; Michael J Gambello
Journal:  Hum Mol Genet       Date:  2012-04-24       Impact factor: 6.150

6.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

Review 7.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

Review 8.  Malformations of cortical development and epilepsy.

Authors:  A James Barkovich; William B Dobyns; Renzo Guerrini
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

Review 9.  New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids.

Authors:  John D Blair; Helen S Bateup
Journal:  Dev Dyn       Date:  2019-05-23       Impact factor: 3.780

10.  Potential Pitfalls in Pre-implantation Genetic Diagnosis in a Patient with Tuberous Sclerosis and Isolated Mosaicism for a TSC2 Variant in Renal Tissue.

Authors:  Kristin M Ikeda; Andrew A House; Dervla M Connaughton; Stephen E Pautler; Victoria Mok Siu; Michelle-Lee Jones
Journal:  Mol Syndromol       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.